MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
Castle Biosciences Book Value 2011-2025 | CSTL
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Castle Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 456 M | 391 M | 399 M | 412 M | 416 M | 85.1 M | -10.1 M | -14.3 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 456 M | -14.3 M | 267 M |
Quarterly Book Value Castle Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 467 M | 455 M | 440 M | 456 M | 441 M | 424 M | 402 M | 391 M | 386 M | 379 M | 385 M | 399 M | 411 M | 422 M | 397 M | 412 M | 412 M | 416 M | 419 M | 416 M | 416 M | 416 M | 416 M | 85.1 M | 85.1 M | 85.1 M | 85.1 M | -10.1 M | -10.1 M | -10.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 467 M | -10.1 M | 330 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M |  USA |
 |
Brainsway Ltd.
BWAY
|
75.7 M | $ 19.29 | -1.73 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 21.26 | -2.34 % | $ 229 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
BioNano Genomics
BNGO
|
35.4 M | $ 1.52 | -0.65 % | $ 1.93 M | USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 231.47 | 0.28 % | $ 169 B | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 10.04 | -0.99 % | $ 285 M | Israel |
 |
DexCom
DXCM
|
2.07 B | $ 67.42 | 0.84 % | $ 26 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | $ 101.54 | -0.05 % | $ 18.8 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 27.01 | -0.55 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
261 M | $ 19.73 | -1.45 % | $ 1.06 B | USA |
 |
Celcuity
CELC
|
116 M | $ 102.61 | 0.25 % | $ 4.05 B | USA |
 |
Anixa Biosciences
ANIX
|
18.9 M | $ 3.42 | 3.64 % | $ 109 K | USA |
 |
Co-Diagnostics
CODX
|
86 M | $ 0.24 | -1.79 % | $ 7.04 M | USA |
 |
IQVIA Holdings
IQV
|
6.07 B | $ 226.02 | 0.39 % | $ 41 B | USA |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
Guardant Health
GH
|
-140 M | $ 102.38 | -0.12 % | $ 12.6 B | USA |
 |
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | USA |
 |
NeoGenomics
NEO
|
902 M | $ 12.3 | -0.97 % | $ 1.56 B | USA |
 |
Neogen Corporation
NEOG
|
2.07 B | $ 7.14 | -0.14 % | $ 1.55 B | USA |
 |
National Research Corporation
NRC
|
49 M | $ 18.81 | -1.05 % | $ 462 M | USA |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
Organovo Holdings
ONVO
|
10.5 M | - | -2.3 % | $ 19.4 M | USA |
 |
OPKO Health
OPK
|
1.37 B | $ 1.3 | -0.76 % | $ 902 M | USA |
 |
OpGen
OPGN
|
7.38 M | - | -16.95 % | $ 1.54 M | USA |
 |
Mettler-Toledo International
MTD
|
-127 M | $ 1 417.16 | 0.18 % | $ 30.1 B |  Schweiz |
 |
Illumina
ILMN
|
6.3 B | $ 135.32 | -0.64 % | $ 21.5 B | USA |
 |
Charles River Laboratories International
CRL
|
3.51 B | $ 203.16 | 0.14 % | $ 10.4 B | USA |
 |
ENDRA Life Sciences
NDRA
|
2.56 M | $ 5.1 | - | $ 2.74 M | USA |
 |
Pacific Biosciences of California
PACB
|
701 M | $ 1.88 | 3.3 % | $ 477 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
12 B | $ 26.98 | 0.37 % | $ 20 B |  Niderland |
 |
PerkinElmer
PKI
|
7.67 B | - | -0.91 % | $ 14.7 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 175.92 | 0.48 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
20.9 M | $ 6.82 | 1.04 % | $ 884 M | USA |
 |
Personalis
PSNL
|
203 M | $ 8.41 | -0.12 % | $ 498 M | USA |
 |
Precipio
PRPO
|
14.4 M | $ 23.89 | 2.56 % | $ 31 M | USA |
 |
Myriad Genetics
MYGN
|
701 M | $ 6.55 | -0.15 % | $ 593 M | USA |